+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Europe Sexually Transmitted Diseases Testing Market By Disease Type, By the Location of Testing Testing, By Country, Opportunity Analysis and Industry Forecast, 2021-2027

  • PDF Icon

    Report

  • 93 Pages
  • January 2022
  • Region: Europe
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5552976
The Europe Sexually Transmitted Diseases (STD) Testing Market is expected to witness market growth of 4.0% CAGR during the forecast period (2021-2027).

The growth of the sexually transmitted diseases (STD) testing market are increased public awareness and patient education. Furthermore, rising number of education programmes, and an increase in government initiatives is expected to fuel the demand for STD testing. In the last decade, the frequency and incidence of STDs have increased dramatically. Several countries around the world are highly focusing on implementing nationwide screening programmes to boost STD diagnosis coverage. Additionally, reimbursement policies for STD services have been beneficial for patients, which is further contributing considerably to the growth of STD testing market.

HIV/AIDS prevention, treatment, and care are gaining more significance in Europe over the last few decades. In the WHO European Region, where no country has been spared, more than two million individuals are infected with the disease. Despite the fact that this number is low when compared to the worst-affected region, it marks an unprecedented spike in new cases. The rapid spread of HIV in Eastern Europe, in particular, is one of the region's most pressing public health issues. In addition, Europe is likely to provide the most instructive combination of both actual success stories (from the region's western and central parts) and cautionary tales of missed possibilities (from its eastern part).

The Germany market dominated the Europe Sexually Transmitted Diseases (STD) Testing Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $8.07 billion by 2027. The UK market is estimated to witness a CAGR of 3.3% during (2021 - 2027). Additionally, The France market is expected to experience a CAGR of 4.8% during (2021 - 2027).

Based on Disease Type, the market is segmented into Chlamydia, Herpes simplex, Gonorrhea, Syphilis, Human papillomavirus (HPV), and Other Disease. Based on the Location of Testing, the market is segmented into Laboratory Testing and Point of care (POC) Testing. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., DiaSorin Molecular LLC, Danaher Corporation, Bio-Rad Laboratories, Inc., and OraSure Technologies, Inc.

Scope of the Study


Market Segments Covered in the Report:


By Disease Type

  • Chlamydia
  • Herpes simplex
  • Gonorrhea
  • Syphilis 
  • Human papillomavirus (HPV)
  • Other Disease

By Location of Testing

  • Laboratory Testing
  • Point of care (POC) Testing

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players


List of Companies Profiled in the Report:

  • BioMérieux S.A.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • DiaSorin Molecular LLC
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • OraSure Technologies, Inc.

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Sexually Transmitted Diseases (STD) Testing Market, by Disease Type
1.4.2 Europe Sexually Transmitted Diseases (STD) Testing Market, by Location of Testing
1.4.3 Europe Sexually Transmitted Diseases (STD) Testing Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Product Launches and Product Expansions 2019, Oct - 2021, Dec) Leading Players
Chapter 4. Europe Sexually Transmitted Diseases (STD) Testing Market by Disease Type
4.1 Europe Chlamydia Market by Country
4.2 Europe Herpes simplex virus Market by Country
4.3 Europe Gonorrhea Market by Country
4.4 Europe Syphilis Market by Country
4.5 Europe Human papillomavirus (HPV) Market by Country
4.6 Europe Other Disease Market by Country
Chapter 5. Europe Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
5.1 Europe Laboratory Testing Market by Country
5.2 Europe Point of care (POC) Testing Market by Country
Chapter 6. Europe Sexually Transmitted Diseases (STD) Testing Market by Country
6.1 Germany Sexually Transmitted Diseases (STD) Testing Market
6.1.1 Germany Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.1.2 Germany Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.2 UK Sexually Transmitted Diseases (STD) Testing Market
6.2.1 UK Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.2.2 UK Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.3 France Sexually Transmitted Diseases (STD) Testing Market
6.3.1 France Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.3.2 France Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.4 Russia Sexually Transmitted Diseases (STD) Testing Market
6.4.1 Russia Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.4.2 Russia Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.5 Spain Sexually Transmitted Diseases (STD) Testing Market
6.5.1 Spain Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.5.2 Spain Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.6 Italy Sexually Transmitted Diseases (STD) Testing Market
6.6.1 Italy Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.6.2 Italy Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
6.7 Rest of Europe Sexually Transmitted Diseases (STD) Testing Market
6.7.1 Rest of Europe Sexually Transmitted Diseases (STD) Testing Market by Disease Type
6.7.2 Rest of Europe Sexually Transmitted Diseases (STD) Testing Market by Location of Testing
Chapter 7. Company Profiles
7.1 BioMérieux S.A.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Research & Development Expenses
7.2 Abbott Laboratories
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments
7.2.5.1 Approvals and Trials
7.3 Becton, Dickinson and Company
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments
7.3.5.1 Product Launches and Product Expansions
7.4 Hologic, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments
7.4.5.1 Approvals and Trials
7.4.5.2 Product Launches and Product Expansions
7.4.5.3 Acquisition and Mergers:
7.5 Thermo Fisher Scientific, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments
7.5.5.1 Partnerships, Collaborations, and Agreements
7.5.6 SWOT Analysis
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments
7.6.5.1 Partnerships, Collaborations, and Agreements
7.6.5.2 Product Launches and Product Expansions
7.7 DiaSorin Molecular LLC
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expenses
7.8 Danaher Corporation
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Bio-Rad laboratories, Inc.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments
7.9.5.1 Acquisition and Mergers:
7.10. OraSure Technologies, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional & Segmental Analysis
7.10.4 Research & Development Expenses
7.10.5 Recent strategies and developments
7.10.5.1 Product Launches and Product Expansions
7.10.5.2 Acquisition and Mergers:

Companies Mentioned

  • BioMérieux S.A.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • DiaSorin Molecular LLC
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • OraSure Technologies, Inc.

Methodology

Loading
LOADING...